Abstract. Genome-wide association studies (GWAS) have facilitated a substantial and rapid rise in the number of confirmed genetic susceptibility variants for type 2 diabetes (T2D). Approximately 40 variants have been identified so far, many of which were discovered through GWAS. This success has led to widespread hope that the findings will translate into improved clinical care for the increasing numbers of patients with diabetes. Potential areas or clinical translation include risk prediction and subsequent disease prevention, pharmacogenetics, and the development of novel therapeutics. However, the genetic loci so far identified account for only a small fraction (approximately 10%) of the overall heritable risk for T2D. Uncovering the missing heritability is essential to the progress of T2D genetic studies and to the translation of genetic information into clinical practice.
NeArly 300 million people worldwide are affected by diabetes mellitus, and its increasing prevalence is a serious concern in many countries. Type 2 diabetes (T2D) is characterized by insulin resistance in peripheral tissues and dysregulated insulin secretion by pancreatic beta-cells. Although the current rise in T2D prevalence is driven mainly by changes in life-style, complex genetic determinants are widely considered to contribute to an inherent susceptibility to this disease. The pathogenesis of T2D is heterogeneous, suggesting that the contribution from individual genetic factors is modest. Linkage analysis and the candidate gene approach were the primary methods to link genotype and phenotype before the development of genomewide association studies (GWAS). Although these techniques can detect rare genetic variants that strongly influence disease susceptibility, they are not suitable to identify variants that have a smaller effect on disease susceptibility. Therefore, the discovery of novel T2D susceptible loci has been challenging, and a more powerful strategy was needed to overcome this difficulty.
The development of high-throughput genotyping technologies and statistical and computational software has allowed remarkable progress over the past decade in the "genome-wide" search for genetic associations. Since the first GWAS for T2D identified novel susceptibility loci in 2007, approximately 40 T2D susceptibility loci have been identified so far, most of them through GWAS.
This review summarizes recent advances in the field of T2D genetics and discusses current obstacles to applying knowledge to clinical applications, as well as future investigations for further understanding of the genetic basis of T2D.
Genetics of T2D: before the GWAS era
Prior to the GWAS era, the importance of genetic factors in the etiology of T2D had been well established through family and twin studies [1, 2] . The primary methods to identify susceptibility loci for diseases or phenotypic traits were linkage analysis and candidategene association studies. Linkage analysis is useful for identifying familial genetic variants that have large effects and was successfully used to discover several causal mutations for the monogenic forms of diabetes mellitus, such as maturity-onset diabetes of the young (MODY) [3] . For the common form of T2D, the dis-International HapMap project. Several million SNPs were discovered and confirmed by the International HapMap project and have been deposited in a public database [18] . The HapMap project initially genotyped 3.9 million SNPs in 270 DNA samples from 4 different ethnic groups and defined the underlying patterns of the inheritance of genetic variation, as quantified by LD. Two SNPs with strong LD are thought to be coinherited more frequently than SNPs with weak LD. Using this correlation structure, association analyses can be made in a more efficient and cost-effective manner by using a smaller subset of SNPs or "tag" SNPs to capture most of the remaining common genetic variations. Thus far, 1000 Genomes Project has been performed and has increased SNP information across the entire human genome, and more than 2 million directly genotyped and imputed SNPs (estimations based on the degree of LD in typed-alleles) can be examined in current GWAS.
The finding that a particular SNP is present at higher frequency in the disease cases versus the controls suggests that the SNP is associated with the disease, and a statistical P value of 5 x 10 -8 is required to satisfy genome-wide significance [19] . Because each GWAS typically involves hundreds of thousands of simultaneous tests of association, this stringent threshold reflects the standard P value of 0.05 with a Bonferroni correction for 1 million statistical tests and effectively reduces the number of false-positive SNPs identified. Even with such strict statistical thresholds, positive findings are routinely replicated in independent datasets to verify or refute the association of a SNP with the phenotype of interest. The data from several casecontrol collections can be merged and summarized by meta-analysis, and this has enabled identification of SNPs with smaller effect size by increasing the overall sample size. At present, 3 conditions must be satisfied to be considered susceptible loci through GWAS: (1) sufficient sample size in the genome-wide scan (at least 1000 each of cases and controls), (2) association P-value at the genome-wide significance level (P< 5 x 10 -8 ), and (3) confirmation of the association by independent replication studies [19] . To date, GWAS have identified nearly 40 susceptibility loci for T2D in European and Asian populations ( Table 1) .
The first GWAS for T2D was conducted in a French cohort composed of 661 cases and 614 controls, covering 392,935 SNP loci. This study identified novel association signals at SLC30A8, HHEX, LOC387761, covery of calpain 10 (CAPN10) in a Mexican-American population was the first reported success of linkage-positional cloning strategy for the disease [4] , although the association could not be robustly replicated in other ethnic groups. Reynisdottir et al. identified segments in chromosomes 5 and 10 with suggestive linkage to T2D [5] , and showed that the chromosome 10 region harbored the TCF7L2 [6] . Five single nucleotide polymorphisms (SNPs) and 1 tetranucleotide repeat polymorphism (DG10S478) within TCF7L2 showed strong association with T2D in 3 independent cohorts, and the SNPs (rs12255372 and rs7903146) showed strong linkage disequilibrium (LD) with composite at-risk alleles of the microsatellite marker (DG10S478). The association between the SNPs (rs12255372 and rs7903146) and decreased insulin secretion was also reported in American subjects with impaired glucose tolerance [7] . Subsequently, the association of TCF7L2 with T2D was replicated not only in populations of European origin but also in other ethnic groups [8] [9] [10] [11] [12] [13] , including the Japanese [14, 15] .
Candidate-gene association studies showed that the genes for the peroxisome proliferator activated receptor gamma (PPARG) [16] and the potassium inwardly rectifying channel subfamily J member 11 (KCNJ11) [17] were 2 candidate susceptibility genes. Both genes encode targets of anti-diabetes medications (thiazolidinediones and sulphonylureas, respectively) and harbor missense variants associated with T2D: P12A in PPARG and E23K in KCNJ11. The successful identification of these genes encouraged the genetic study of T2D; however, the limitations of these classical approaches were also recognized. Thus, it has been challenging to identify the specific genetic variants associated with an increased risk for T2D, and until recently, these genes were largely unknown.
The GWAS era of T2D genetics
A significant breakthrough in understanding the genetic basis of complex traits including T2D, was facilitated by the arrival of GWAS. GWAS is a powerful biology-agnostic method to detect genetic variations that predispose to a disease. In GWAS, the entire genomes of individuals with and without the disorder of interest (i.e., cases and controls) are screened for a large number of common SNPs. These studies have been facilitated by several recent developments including completion of the Human Genome Project and the T2D genetics References are in brackets
GWAS for continuous glycemic traits
Studies examining diabetes-related quantitative traits in participants without diabetes have also identified loci that influence beta-cell function and insulin resistance ( Table 2) . GWAS showed that G6PC2 and MTNR1B were associated with fasting-glucose levels [28] [29] [30] , and further studies confirmed the association of these 2 loci [29-31] and GCK which had been identified by the candidate-gene approach [32] . Recently, the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) examined 21 GWAS to identify loci associating with fasting glucose, fasting insulin, HOMA-β, and HOMA-IR [33] . Collectively, the GWAS included 46,186 participants of European descent and analyzed more than 2.5 million genotyped or imputed SNPs. After replication among 76,558 individuals from 34 additional cohorts, 9 new loci in or near ADCY5, MADD, CRY2, ADRA2A, FADS1, PROX1, SLC2A2, GLIS3, and C2CD4B were found to be associated with fasting glucose. In addition, GCKR and a SNP upstream of IGF1 were found to be associated with fasting insulin and HOMA-IR. The metaanalysis also confirmed prior associations for glycemic traits with SNPs in or near DGKB-TMEM195, GCKR, G6PC2, MTNR1B, and GCK. An aggregate genotype score was constructed by summing the 16 risk variants and showed a clinically relevant difference in fasting glucose concentrations of about 7.2 mg/dL between groups with the highest and lowest scores. Five loci for 2-hour glucose levels, GIPR, ADCY5, GCKR, VPS13C, and TCF7L2 were further identified in a meta-analysis of 9 GWAS for 2-hour glucose and subsequent replication studies [34] .
Among the loci identified as being associated with glycemic traits, MTNR1B, GCK, ADCY5, PROX1, DGKB-TMEM195, and GCKR were also identified as novel loci associated with T2D.
GWAS in groups of non-european descent
Over the past 2 decades, many Asian countries have experienced a dramatic increase in the incidence of T2D. Cumulative evidence suggests that Asians may be more susceptible than populations of European ancestry to insulin resistance and diabetes, which was thought to be due to interethnic genetic inheritance [35] . Several of the T2D loci identified by European GWAS, especially the first round of GWAS, have been conand EXT2 and validated the previously identified association at TCF7L2 [20] . Shortly after the initial GWAS, the Icelandic company deCODE Genetics and their collaborators confirmed the association between T2D and SLC30A8, HHEX, and the newly identified CDKAL1 [21] . At the same time, 3 collaborating groups, the Wellcome Trust Case Control Consortium/ United Kingdom Type 2 Diabetes Genetics consortium (WTCCC/UKT2D), the Finland-United States Investigation of NIDDM (FUSION), and the Diabetes Genetics Initiative (DGI), published their findings replicating the association of SCL30A8 and HHEX with T2D and independently discovering novel associations at CDKAL1, IGF2BP2, and CDKN2A/B [22] [23] [24] . With the exception of LOC387761 and EXT2, these novel loci and 2 previously-known variants, PPARG P12A and KCNJ11 E23K, were confirmed by multiple replication studies composed of European and non-European populations. Thus, the first round of European GWAS confirmed 8 T2D susceptibility loci across multiple ethnic groups: TCF7L2, SLC30A8, HHEX, CDKAL1, IGF2BP2, CDKN2A/B, PPARG, and KCNJ11. In addition to these 8 loci, the WTCCC/UKT2D study identified a strong association between FTO variants and T2D, although the effect of FTO variants on conferring susceptibility to T2D was mostly mediated through increase in body weight [25] .
After the first round of European GWAS, an effort was made to increase sample size so that common variants with lower effect sizes would be detectable. WTCCC/UKT2D, FUSION, and DGI combined their data to form the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium. Five additional novel loci, JAZF1, CDC123/CAMK1D, TSPAN/ LGR5, THADA, and ADAMSTS9, were identified in a genome-wide scan comprising a substantial sample size (4,549 cases and 5,579 controls) followed by replication testing and more than 2.2 million SNPs (either directly genotyped or imputed) [26] .
Most of the T2D genetics cohorts have now combined to form DIAGRAM+, which yields an effective sample size of more than 22,000 subjects of European origin. In a recent study, 2,426,886 imputed and genotyped autosomal SNPs, with additional interrogation of the X-chromosome, were examined for association with T2D as a categorical phenotype. Twelve new loci were identified as susceptibility loci for T2D with a genomewide significance association (P < 5 x 10
tify ethnic group-specific T2D susceptibility loci, those were not captured in the European study. In 2008, 2 independent Japanese GWAS identified the KCNQ1 locus as a T2D susceptibility locus [36, 37]; these studies were the first GWAS for T2D using non-European populations. Subsequent replication studies performed in different ethnic groups revealed that variants within the KCNQ1 had the strongest effects on conferring susceptibility to T2D in several East Asian populations [38] [39] [40] [41] . The association of the KCNQ1 locus with T2D could be replicated in European populations, but the minor allele frequencies were considerably lower firmed in Asian populations (Table 1) . However, there are significant interethnic differences in the risk allele frequency at several loci. For example, risk allele frequencies of TCF7L2 SNPs showing the strongest effect on T2D in European populations are very few in the Japanese (~5%) compared to populations of European descent (~40%). As a result, TCF7L2 variants have a little effect on susceptibility to T2D in the Japanese (Table 3 ). In addition, the associations between T2D and some loci are not consistent in Japanese populations. Therefore, to explain T2D heritability in populations of Asian descent, it may be necessary to iden- What have GWAS brought about so far?
Identified loci for T2D linked more frequently to beta-cell function than to insulin sensitivity
The etiology of T2D is a combination of beta-cell dysfunction and insulin resistance, which is promoted by either genetic or environmental factors (e.g., obesity, westernized diet, and life style). Interestingly, most of the known T2D susceptible variants appear to influence insulin secretion rather than insulin resistance. For example, risk variants of CDKAL1, SLC30A8, and HHEX were shown to be associated with an impaired insulin response in glucose tolerance tests [21, [45] [46] [47] [48] . CDKN2A/B variants have been associated with impaired glucose-induced insulin secretion in healthy subjects [46] . In the MAGIC study, all the loci associated with T2D, ADCY5, PROX1, GCK, GCKR, and DGKB-TMEM195 were associated with fasting glucose/HOMA-β, whereas only GCKR was associated with HOMA-IR [33] . Another large meta-analysis from DIAGRAM+ demonstrated that of 31 confirmed T2D susceptibility loci, 10 (MTNR1B, SLC30A8, THADA, TCF7L2, KCNQ1, CAMK1D, CDKAL1, IGF2BP2, HNF1B, and CENTD2) were nominally associated with reduced HOMA-β and only 3 (PPARG, FTO, and KLF14) were associated with HOMA-IR [27] . Furthermore, all loci identified in the Japanese GWAS, namely, KCNQ1, UBE2E2, and C2CD4A-C2CD4B were shown to be associated with decreased beta-cell function in non-diabetic control groups [37, 42, 49] . Prior to the accumulation of GWAS data, a genetic predisposition to insulin resistance had been considered to play the dominant role in development of T2D, especially in populations of European origin. The results obtained from GWAS, however, emphasize the crucial role of the pancreatic beta cells in the onset of T2D, and a genetic predisposition to reduced beta-cell function may contribute more to the susceptibility to T2D. than in East Asian populations (~7% versus ~40%, Table 3 ). Thus, in contrast to TCF7L2, the impact of the KCNQ1 locus on T2D susceptibility was relatively small in European populations. Since the KCNQ1 locus was not captured in the European studies, this finding emphasizes the importance of examining susceptibility loci in different ethnic groups.
Although the 2 previously mentioned Japanese GWAS successfully identified the KCNQ1 locus, these studies had limited sample sizes at the initial stage of the genome-wide scan. T2D has not yet been performed in East Asian populations. Two additional T2D susceptibility loci, UBE2E2 and C2CD4A-C2CD4B, were discovered in 2010 in a Japanese GWAS of a larger sample size (4,470 T2D vs. 3,071 controls) [42] . Associations between the C2CD4A-C2CD4B locus and T2D were confirmed by replication sets for both East Asian and European populations; however, no association between UBE2E2 and T2D was observed in the European population. Therefore, the UBE2E2 variants may affect development of T2D specifically in East Asian populations through interactions with specific environmental factors and/or specific genetic factors other than UBE2E2. However, the possibility that the same UBE2E2 locus (perhaps through the same or different causal variants) is involved in the development of T2D in European populations cannot be excluded until the results of fine mapping and/or re-sequencing studies are available. Recently, the association of 4 loci, PTPRD, SRR, CDC123/CAMK1D, and SPRY2 with T2D were shown to reach a genome-wide significance level in GWAS among Han Chinese in Taiwan and Shanghai [43, 44] . However, the association of these 4 loci remains to be evaluated in independent replication cohorts. [50] , the Malmö Preventive Project (MPP), and the Botnia Study [51] , among others [52, 53] . The studies examined 11 to 20 loci associated with T2D, and a genetic score was calculated based on the number of risk alleles in subjects who developed diabetes during the follow-up period and those who remained disease-free. The results of these analyses showed no clear improvement of predictive power by adding the genetic risk score to established risk prediction models composed of various clinical and biochemical factors including age, sex, family history, body mass index, fasting glucose level, systolic blood pressure, and lipid profile. The area under the receiver operating characteristics (ROC) curves was 0.74 and 0.75 with and without adding the genetic risk score, respectively [51] .
Despite this, subset analyses of the study cohorts suggested that genetic testing might be beneficial in younger patients before clinical manifestation of the phenotypic characteristics associated with T2D. This possibility was recently examined by de Miguel-Yanes and colleagues, who re-calculated the genotype score of the Framingham Offspring Study using the updated list of 40 T2D susceptibility variants [54] . This study showed that the genetic score marginally improved the ability to predict future diabetes in subjects younger than 50 years; the increased risk was 24% per allele for individuals <50 years of age and 11% per allele for people ≥50 years of age.
A genetic investigation suggested no increased risk of T2D in homozygous carriers of the TCF7L2 risk allele who were randomized to the lifestyle intervention arm of the Diabetes Prevention Program (DPP), although carrying both copies of the risk allele usually confers an 80% increased risk of developing diabetes [7] . This is a good example of the clinical usefulness of genetic testing to allow detection of high-risk individuals with whom physicians should aggressively intervene. At present, insufficient information is available to construct a genetic risk score for T2D and it is far from translating into clinical practice. One study, however, reported that a "high risk" result from genetic testing would inspire 71% of the 152 healthy subjects interviewed to adopt healthy lifestyle changes [55] . Therefore, despite the limited ability of genetic testing to predict T2D, genetic information may be more powerful in influencing behavior that will result in a subsequent health benefit.
Missing heritability
GWAS have successfully identified novel T2D susceptibility loci that had not been captured by classical approaches. However, based on the results of a European twin study, only ~10% of the known T2D heritability could be explained by those T2D susceptibility loci [27] . Although there is no information to estimate the T2D heritability in other ethnic populations, the sum of explained variance for all associated loci accounts for less than 20% heritability in the Japanese (our unpublished observation), suggesting the existence of a large portion of "missing heritability." To search for the missing heritability, several limitations of the current strategy for GWAS should be considered.
First, there are a considerable number of uncaptured SNPs in the public database, and there has been insufficient effort to perform GWAS for populations other than those of European origin. Second, the currently accepted significant threshold for GWAS (P < 5 x 10 -8 ) may produce type 2 errors (false-negative results), and it is expected that many important loci are obscured among loci having only borderline associations; these could be captured in larger-scale analyses of different ethnic populations. A third limitation is the role of lowfrequency risk variants that may have relatively large effects. The rationale of GWAS is based on the "common disease-common variant" hypothesis, and studies have focused on finding common variants associated with the disease; therefore, susceptibility variants having a minor allele frequency (MAF) of less than 1% are frequently missed.
Improving on the limitations of GWAS as they are currently performed will uncover other loci contributing to the disease. To overcome these limitations, the genome-wide exon (exome) sequencing strategy should be facilitated by ultra high-throughput sequencing technology (next-generation sequencers). In this analysis, a part of the missing heritability may be explained by identifying the clustering of rare variants within particular genes in the affected individuals. The introduction of next-generation sequencers will also help to solve missing heritability by accelerating studies of the transcriptome, large-scale sequence analysis of small RNAs, and/or epigenetic analyses such as the methylome.
Translation of T2D genetics into clinical practice: the possibility of disease prediction and prevention
One of the most anticipated clinical uses of genetic information is to predict an individual's risk of devel-datasets. The success of these missions, followed by the start of GWAS held out the hope that personalized medicine would be realized within the next several years. The first GWAS data were published in 2007 by WTCCC, and since then, more than 1,100 loci have been discovered [61] . Although this is excellent progress, it has also been recognized that the information obtained from GWAS has been insufficient to improve human health. In the field of T2D, GWAS has identified many new and convincing T2D susceptible loci. This too is an excellent start, but the entire heritability of T2D remains largely unexplained, despite the growing list of T2D susceptibility variants described here.
Over the next few years, certain modifications of the GWAS study design will be necessary. Much larger intra-or trans-ethnic sample sizes will be required to increase the power for detection, which may be conducted in meta-analyses. Examining populations of non-European descent is likely to identify additional T2D loci, and this should be performed more vigorously. An alternative option is subgroup analysis, which could eliminate the phenotypic variations that minimize the power for detection.
Association analyses of rarer variants for T2D are an additional option. In this regard, the search for low-frequency variants will be facilitated by the 1000 Genomes Project [62] . This international collaborative initiative is using next generation whole-genome sequencing technology to systematically catalog all variants with a minor allele frequency of greater than 1% in at least 1000 genomes. Exome sequencing is also an efficient strategy to selectively sequence the coding regions of the human genome to identify novel genes associated with rare and common disorders. Routine whole-genome sequencing of large numbers of individuals is still not feasible, in part due to the high cost associated with the technique, and the exome represents an enriched portion of the genome that can be used to search for variants with large effect sizes.
Further, examining non-additive gene-gene interactions and/or gene-environmental interactions may lead to the discovery of novel pathways that synergize to increase the risk of developing T2D.
Efforts must be made over the coming decade to translate new findings from GWAS to the clinic, which could attract the interest of most endocrinologists. One potential clinical application is the development of genetically based personalized susceptibility profiles to aid in the prediction, early identification, and pre-
Translation of T2D genetics into clinical practice: the possibility of identifying novel therapeutic targets
Although many new and interesting T2D susceptibility loci have been identified, it is challenging to translate them into clinical practice, especially for developing new drugs. A major obstacle is that disease-associated SNPs are usually annotated by the gene in closest proximity; however, the protein encoded by that gene may not have a causative role in the development of T2D in humans. In fact, for most of the identified T2D susceptibility loci, the causal variants and molecular mechanisms for diabetes risk are unknown. Furthermore, most genetic risk variants are found in the intronic or non-coding regions of genes and are more likely to affect regulation of transcription rather than gene function per se, thus being unlikely to be directly linked to the gene's biological function.
Nevertheless, GWAS have provided many useful insights into the pathophysiology of T2D. For example, the first T2D GWAS identified the T2D susceptibility variant rs13266634, which encodes an R →W change at position 325 in the SLC30A8 gene [20] . The SLC30A8 encodes ZnT-8, which transports zinc from the cytoplasm into secretory vesicles for insulin storage and secretion [56] . A therapeutic agent that enhances the intracellular function of this transporter could theoretically increase insulin secretion and lower blood glucose levels. In addition, other T2D susceptibility variants confirmed by GWAS include variants within the genes PPARG and KCNJ11 that encode targets of the established oral hypoglycemic agents, thiazolidinediones and sulphonylureas, respectively [57, 58] . Therefore, elucidating the mechanisms by which each susceptibility locus contributes to T2D will improve our understanding of the pathophysiology of T2D and will provide new and useful information for the development of new drugs for the treatment and/or prevention of T2D.
Future perspective
Ten years have passed since the first draft of the human genome sequence was published [59, 60] . During the past decade, the human genome (sequencing) project was completed, and a large body of information on the human genome has been accumulated. Simultaneously, several high-throughput genotyping technologies have been developed, as well as statistical methods and/or tools for handling innumerable clinical impact to date is not surprising as this branch of genetic research is still in its infancy, and it will be a challenge to translate the GWAS findings into improved care for patients with diabetes. The focus of ongoing research efforts include detailed functional characterization of the identified T2D susceptibility variants and the search for missing heritability. GWAS have produced a significant breakthrough in the field of common disease genetics, but this alone will not provide sufficient information. Translating information on the human genome into clinical practice has proven to be more challenging than was expected in 2003, when the Human Genome Project ended. According to the plan published by the National Human Genome Research Institute on February 2011, the impact of human genome data on health care will begin to build only after 2020 [64] . We still have a long way to go. vention of T2D or its complications.
Pharmacogenetics is also a promising clinical application of the genetic findings for T2D. Genetic profiling may allow personalized medicine by facilitating optimal treatment choices that maximize clinical efficacy and minimize toxicity. Recently, a GWAS of the glycemic response to metformin identified a SNP associated with treatment success at a locus containing the ataxia telangiectasia mutated gene (ATM) [63] . Although genetic background alone is insufficient to predict treatment response at an individual level, accumulation of these pharmacogenetic data is necessary for the future development of personalized medicine.
Conclusion
The exciting results generated by GWAS have led to intense discussion of their clinical utility. The lack of 
